Literature DB >> 22842843

Receptor activator of nuclear factor-κB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients.

Janice J Hwang1, Jeffrey Wei, Suhny Abbara, Steven K Grinspoon, Janet Lo.   

Abstract

HIV-infected individuals have an increased prevalence of coronary artery disease. Receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin have been postulated as mediators of vascular calcification. 78 HIV-infected men and 32 healthy controls without history of coronary artery disease were prospectively recruited to undergo cardiac computed tomography and computed tomography angiography to assess coronary artery calcium and plaque burden. Soluble receptor activator of nuclear factor-κB ligand was lower in HIV-infected individuals than controls [2.52 (1.08-3.98) vs. 3.33 (2.44-4.64) pg/mL, P = 0.01, median (IQR) respectively]. Soluble receptor activator of nuclear factor-κB ligand was negatively associated with the number of coronary segments with plaque (Spearman ρ = -0.41, P < 0.001) and Agatston calcium score (ρ = -0.30, P < 0.01) in HIV-infected individuals even after adjusting for traditional cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22842843      PMCID: PMC3766949          DOI: 10.1097/QAI.0b013e31826a6c16

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  24 in total

1.  Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men.

Authors:  Michael Schoppet; Juergen R Schaefer; Lorenz C Hofbauer
Journal:  Circulation       Date:  2003-03-25       Impact factor: 29.690

2.  A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association.

Authors:  W G Austen; J E Edwards; R L Frye; G G Gensini; V L Gott; L S Griffith; D C McGoon; M L Murphy; B B Roe
Journal:  Circulation       Date:  1975-04       Impact factor: 29.690

3.  Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes.

Authors:  Jang Yel Shin; Young Goo Shin; Choon Hee Chung
Journal:  Diabetes Care       Date:  2006-07       Impact factor: 19.112

4.  The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects.

Authors:  Dhakshinamurthy Vijay Anand; Avijit Lahiri; Eric Lim; David Hopkins; Roger Corder
Journal:  J Am Coll Cardiol       Date:  2006-04-19       Impact factor: 24.094

5.  Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction.

Authors:  Alessandra Crisafulli; Antonio Micari; Domenica Altavilla; Francesco Saporito; Aurora Sardella; Maria Passaniti; Santi Raffa; Gaspare D'anneo; Fabiana Lucà; Chiara Mioni; Francesco Arrigo; Francesco Squadrito
Journal:  Clin Sci (Lond)       Date:  2005-10       Impact factor: 6.124

6.  Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization.

Authors:  Wiggo J Sandberg; Arne Yndestad; Erik Øie; Camilla Smith; Thor Ueland; Olga Ovchinnikova; Anna-Karin L Robertson; Fredrik Müller; Anne G Semb; Hanne Scholz; Arne K Andreassen; Lars Gullestad; Jan Kristian Damås; Stig S Frøland; Göran K Hansson; Bente Halvorsen; Pål Aukrust
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-01-19       Impact factor: 8.311

7.  HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk.

Authors:  J Mohamad Fakruddin; Jeffrey Laurence
Journal:  J Biol Chem       Date:  2003-09-15       Impact factor: 5.157

8.  The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling.

Authors:  Michael W-H Wang; Shi Wei; Roberta Faccio; Sunao Takeshita; Pablo Tebas; William G Powderly; Steven L Teitelbaum; F Patrick Ross
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis.

Authors:  Jonathan Golledge; Moira McCann; Simone Mangan; Alfred Lam; Mirko Karan
Journal:  Stroke       Date:  2004-05-13       Impact factor: 7.914

10.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Authors:  D M Anderson; E Maraskovsky; W L Billingsley; W C Dougall; M E Tometsko; E R Roux; M C Teepe; R F DuBose; D Cosman; L Galibert
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

View more
  12 in total

1.  Osteoprotegerin, but Not Receptor Activator for Nuclear Factor-κB Ligand, is Associated With Subclinical Coronary Atherosclerosis in HIV-Infected Men.

Authors:  Kerunne S Ketlogetswe; Rebeccah McKibben; Lisa P Jacobson; Xuihong Li; Adrian S Dobs; Matthew Budoff; Mallory D Witt; Frank J Palella; Lawrence Kingsley; Joseph B Margolick; Wendy S Post; Todd T Brown
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-01       Impact factor: 3.731

Review 2.  Serum biomarkers for arterial calcification in humans: A systematic review.

Authors:  Nienke M S Golüke; Marit A Schoffelmeer; Annemarieke De Jonghe; Mariëlle H Emmelot-Vonk; Pim A De Jong; Huiberdina L Koek
Journal:  Bone Rep       Date:  2022-06-18

3.  Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study.

Authors:  Jordan E Lake; Sophie Seang; Theodoros Kelesidis; Diana H Liao; Howard N Hodis; James H Stein; Judith S Currier
Journal:  HIV Clin Trials       Date:  2015-09-11

4.  Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s.

Authors:  Theodoros Kelesidis; Carlee B Moser; Elizabeth Johnston; James H Stein; Michael P Dube; Otto O Yang; Grace A McComsey; Judith S Currier; Todd T Brown
Journal:  J Acquir Immune Defic Syndr       Date:  2018-07-01       Impact factor: 3.771

5.  Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin.

Authors:  Alessandra D'Abramo; Claudia D'Agostino; Alessandra Oliva; Marco Iannetta; Gabriella D'Ettorre; Francesco Vullo; Massimo Mancone; Maria Rosa Ciardi; Claudio Maria Mastroianni; Vincenzo Vullo
Journal:  ISRN AIDS       Date:  2013-12-05

6.  Immune activation, immunosenescence, and osteoprotegerin as markers of endothelial dysfunction in subclinical HIV-associated atherosclerosis.

Authors:  Alessandra D'Abramo; Maria Antonella Zingaropoli; Alessandra Oliva; Claudia D'Agostino; Samir Al Moghazi; Giulia De Luca; Marco Iannetta; Claudio Maria Mastroianni; Vincenzo Vullo
Journal:  Mediators Inflamm       Date:  2014-10-14       Impact factor: 4.711

7.  Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection.

Authors:  Kehmia Titanji; Aswani Vunnava; Anandi N Sheth; Cecile Delille; Jeffrey L Lennox; Sara E Sanford; Antonina Foster; Andrea Knezevic; Kirk A Easley; M Neale Weitzmann; Ighovwerha Ofotokun
Journal:  PLoS Pathog       Date:  2014-11-13       Impact factor: 6.823

8.  Distribution of alkaline phosphatase, osteopontin, RANK ligand and osteoprotegerin in calcified human carotid atheroma.

Authors:  Catherine L Higgins; Salim Isbilir; Pamela Basto; Iou Yih Chen; Muthiah Vaduganathan; Periyanan Vaduganathan; Michael J Reardon; Gerald Lawrie; Leif Peterson; Joel D Morrisett
Journal:  Protein J       Date:  2015-10       Impact factor: 2.371

9.  Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study.

Authors:  Theodoros Kelesidis; Michelle A Kendall; Otto O Yang; Howard Hodis; Judith S Currier
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-25       Impact factor: 1.723

Review 10.  Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.

Authors:  Theodoros Kelesidis; Judith S Currier; Otto O Yang; Todd T Brown
Journal:  AIDS Rev       Date:  2014 Jul-Sep       Impact factor: 2.381

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.